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Abstract
Background: Cancer stem cells (CSCs) have increased resistance to cancer chemotherapy. They can be enriched as drug-
surviving CSCs (D-CSCs) by growth with chemotherapeutic drugs, and/or by sorting of cells expressing CSC markers such as
aldehyde dehydrogenase-1 (ALDH). CSCs form colonies in agar, mammospheres in low-adherence cultures, and tumors
following xenotransplantation in Scid mice. We hypothesized that tranilast, a non-toxic orally active drug with anti-cancer
activities, would inhibit breast CSCs.
Methodology/Findings: We examined breast cancer cell lines or D-CSCs generated by growth of these cells with
mitoxantrone. Tranilast inhibited colony formation, mammosphere formation and stem cell marker expression.
Mitoxantrone-selected cells were enriched for CSCs expressing stem cell markers ALDH, c-kit, Oct-4, and ABCG2, and
efficient at forming mammospheres. Tranilast markedly inhibited mammosphere formation by D-CSCs and dissociated
formed mammospheres, at pharmacologically relevant concentrations. It was effective against D-CSCs of both HER-2+ and
triple-negative cell lines. Tranilast was also effective in vivo, since it prevented lung metastasis in mice injected i.v. with
triple-negative (MDA-MB-231) mitoxantrone-selected cells. The molecular targets of tranilast in cancer have been unknown,
but here we demonstrate it is an aryl hydrocarbon receptor (AHR) agonist and this plays a key role. AHR is a transcription
factor activated by 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), polycyclic aromatic hydrocarbons and other ligands.
Tranilast induced translocation of the AHR to the nucleus and stimulated CYP1A1 expression (a marker of AHR activation). It
inhibited binding of the AHR to CDK4, which has been linked to cell-cycle arrest. D-CSCs expressed higher levels of the AHR
than other cells. Knockdown of the AHR with siRNA, or blockade with an AHR antagonist, entirely abrogated the anti-
proliferative and anti-mammosphere activity of tranilast. Thus, the anti-cancer effects of tranilast are AHR dependent.
Conclusion/Significance: We show that tranilast is an AHR agonist with inhibitory effects on breast CSCs. It is effective
against CSCs of triple-negative breast cancer cells selected for anti-cancer drug resistance. These results suggest it might
find applications in the treatment of breast cancer.
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Introduction
Cancer stem cells (CSCs), also denoted cancer initiating cells
(CIC), have increased resistance to cancer chemotherapy, and there
is an urgent need to identify drugs that target these cells. They were
first identified in human leukemias [1], and more recently in solid
tumors[2,3].A minimaldefinition ofCSCshasthree features[2–4]:
1) Distinct markers allowing purification; 2) highly tumorigenic as
compared to other subsets; and 3) ability to differentiate to recreate
all cell phenotypes of the parent tumor. There are several other
notable features such as self-renewal, the capacity to form tumor
spheres in low-adherence cultures, expression of high levels of ATP-
binding cassette (ABC) drug transporters (especially ABCG2) and
multi-drug resistance. Human breast cancer cell lines (e.g., MDA-
MB-231, BT474 and SUM159) can be fractionated into subpop-
ulations, some of which have CSC properties and form mammo-
spheres in vitro. CSCs can be isolated by fluorescence-activated cell
sorting (FACS) within the Hoescht 33342 dye-excluding side
population (SP) [5], or the aldehyde dehydrogenase-1 high
(ALDH
hi) population [6,7]. Importantly, recent studies [8–10] have
shown that CSC-likecellscanalsobe enriched from cancercelllines
by growth with conventional chemotherapeutic drugs (e.g.,
doxorubicin, cisplatin, etoposide, mitoxantrone). In this study, we
generated drug-surviving CSCs (D-CSCs) by growing breast cancer
cells in mitoxantrone. The growth of breast cancer cell lines in
medium containing mitoxantrone resulted in a marked enrichment
of cells with CSC-like markers (ALDH
hi, c-kit, Oct-4 and ABCG2)
and functional characteristics. This method has the advantage of
selecting the cells for a property (drug resistance) that is highly
relevant to cancer therapy.
PLoS ONE | www.plosone.org 1 November 2010 | Volume 5 | Issue 11 | e13831We hypothesized that tranilast, a drug with anti-proliferative
and anti-cancer activities [11–13], would inhibit CSCs. It is a non-
toxic orally active drug developed for allergic diseases [14], but
that we found targets breast cancer cells through multiple
pathways [12,13]. Tranilast inhibits the following: cell cycling,
TGF-b activity, MAPK signaling, epithelial-to-mesenchymal
transition (EMT), cell migration and invasion. In vivo, it has
prominent anti-metastatic effects [12]. Here we show that tranilast
strongly inhibits CSCs in colony forming assays and mammo-
sphere formation assays, at pharmacologically relevant concentra-
tions. Tranilast was highly active at inhibiting mammosphere
formation by D-CSCs, and dissociating formed mammospheres. It
was effective in vivo, preventing metastasis to the lungs following
i.v. injection of MDA-MB-231 mitoxantrone-selected cells.
The molecular target(s) of tranilast in cancer have been unclear,
but we demonstrate here that it is an aryl hydrocarbon receptor
(AHR) agonist. The AHR is a transcription factor known
principally as a receptor for toxins such as 2,3,7,8-tetrachlorodi-
benzo-p-dioxin (TCDD) [15], but it has other functions [16] and
appears to exert some anti-cancer effects [17,18]. We show that
tranilast binds to the AHR, induces its translocation to the nucleus,
and stimulates CYP1A1 expression (a classic marker of AHR
activity). D-CSCs expressed increased amounts of AHR. Knock-
down of the AHR with siRNA, or addition of an AHR antagonist
to cultures, both abolished the activity of tranilast in vitro. Thus,
the activity of tranilast appears to be highly AHR dependent.
We also show that tranilast is effective at inhibiting CSCs of
triple-negative (ER2/PR2/HER-22) breast cancer cell lines
(MDA-MB-231, SUM149 and SUM159) or a triple-positive cell
line (ER+/PR+/HER-2+) (BT474). This is particularly relevant
because triple-negative cells have lacked a distinct molecular target
and their treatment is problematic. Recent studies suggest that the
AHR is an excellent target for breast cancer therapy [17,18], and
tranilast appears to be an exceptional drug for this purpose.
Results
Inhibition of colony formation and mammosphere
formation by tranilast
One property of CSCs is the ability to form colonies in soft agar.
When tranilast was added to cultures of MDA-MB-231 or BT474
breast cancer cells at 200 mM there was marked inhibition of
colony formation (Fig. 1A–C). The colonies were significantly
fewer and smaller. Note that the MDA-MB-231 colonies,
compared to BT474, are not as round and their borders are less
clearly defined. We have found this to be a regular feature of
MDA-MB-231 colonies.
Another property of CSCs is the ability to form tumor spheres,
denoted mammospheres in the case of breast cancer. Unselected
breast cancer cells (parental population) of different phenotype
[19,20] were plated in serum-free, low adherence cultures to
generate mammospheres. Cells derived from the MDA-MB-231
cell line (ER
2/PR
2/HER-2
2 triple-negative cell line) (Fig. 2A,B),
or the BT474 cell line (ER
+/PR
+/HER-2
+ triple-positive)
(Fig. 2C), both readily formed mammospheres in this assay. The
shape and appearance of the spheres was cell-line dependent, and
BT474 cells tended to form round spheres, while MDA-MB-231
mammospheres were looser and less rounded. Tranilast markedly
inhibited the formation of mammospheres in primary and
secondary mammosphere assays of these cells lines (Fig. 2A–D).
Furthermore, Western blotting studies revealed that tranilast
suppressed the phosphorylation of retinoblastoma protein (RB),
and the expression of CSC markers CD133 and Oct-4 in MDA-
MB-231 mammosphere cultures (Fig. 2E).
To determine whether tranilast eliminated sphere-forming
CSCs, we isolated cells grown with tranilast, as in Fig. 2A, and
replated the cells in mammosphere cultures without tranilast (Fig.
S1A). The replated cells formed mammospheres, indicating that at
least a portion of sphere forming cells survived incubation with
tranilast. This is consistent with our previous findings that tranilast
is not markedly cytotoxic [12]. Nevertheless, tranilast reduced cell
survival (Fig. S1B) in mammosphere culture, as discussed below.
Isolation of D-CSCs
There are no completely specific markers of breast CSCs, but
the cells can be enriched by sorting for some markers such as
CD44+/CD24-(or low)/ESA+ [19] or ALDH
hi expression
(ALDEFLUOR reaction) [6,7]. However, there is limited
correlation in the expression of these markers in different studies,
and some cell lines such as MDA-MB-231 consist mainly of
CD44
+/CD24
2 cells. An alternative approach to enriching CSCs
involves the isolation of drug-surviving CSC-like cells, that we
denote D-CSCs, as described by Levina et al. [8] and others
[9,10]. In this case, the cells which survive culture with
doxorubicin, mitoxantrone or other drugs are highly enriched in
Figure 1. Tranilast treatment reduces colony size and numbers.
A and B. Colony forming assay using soft agar of MDA-MB-231 cells (A)
or BT474 cells (B). In both cases we observed a reduction in colony size
in tranilast treated cells when compared to the vehicle control (day 12,
400x). C. The colony numbers of BT474 were significantly reduced
(mean + SD, *p,0.05). Reduction in colony numbers with MDA-MB-231
cells was equally significant (not shown). Results shown are the mean of
2 independent experiments in triplicates.
doi:10.1371/journal.pone.0013831.g001
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produced D-CSCs by growing breast cancer cell lines, such as
MDA-MB-231 and BT474, in mitoxantrone-containing medium.
After 5 days of mitoxantrone exposure, the cells were transferred
to mitoxantrone-free culture medium for another 3–5 days before
further studies were performed. As detected by flow cytometric
analysis (Fig. 3A,B) or confocal microscopy (Fig. 3C) the
mitoxantrone-selected cells were markedly enriched for CSC
marker expression, including ALDH
hi, c-kit, ABCG2 and Oct-4.
There was also increased expression of the AHR (Fig. 3B). Hence,
although the AHR is expressed by the parental cells and is not a
specific CSC marker, its expression was markedly increased by
mitoxantrone (see below).
Thus, the drug-selected cells were markedly enriched in cells
with CSC markers, with 30–50% of the cells expressing at least
one of these markers. The high level of expression of ABCG2 is
consistent with the ability of this drug transporter to pump
mitoxantrone out of the cells [21,22]. In addition, by qRT-PCR
array analysis (SABiosciences), the D-CSCs overexpress (.2-fold)
several stem-cell related genes compared to the parental line (e.g.,
ABCG2, ALDH-1, BMPs, FGFs, desert hedgehog, WNT1) (data
not shown). The drug-surviving cells also formed mammospheres
at higher frequency as detailed below.
Activityoftranilast againstmammosphere-formingD-CSCs
Previously [12], we found that a rat mammary carcinoma line
with stem cell features (LA7) was highly sensitive to tranilast.
Furthermore, tranilast inhibited EMT [12], which has been linked
to the CSC phenotype [23,24]. Mammosphere culture has been
shown to enrich for tumorigenic breast cancer cells [25]. Here, we
show that when tranilast was added to mammospheres that were
already formed, generated from mitoxantrone-selected MDA-MB-
231 (human) or 4T1 (mouse) cells, the spheres dissociated within
48 h (Fig. 4A). Tranilast also dissociated mammospheres produced
by other breast cancer cell lines including BT474, SUM149 and
SUM159 (Fig. 4B). Dissociation of the tranilast-treated spheres
was associated with increased cell death, but $50% of cells were
still alive after dissociation (trypan blue dye exclusion assay; not
shown), suggesting that it was not due to cell death alone. The
dissolution of existing spheres is an important finding, because it
suggests that the anti-mammosphere effect of tranilast is not solely
due to an inhibition of proliferation.
Mitoxantrone-selected cells formed mammospheres at a higher
frequency (Fig. 5) than unselected cells (Fig. 2D). Tranilast inhibited
formation of mammospheres from mitoxantrone-selected MDA-
MB-231 cells when it was added at the start of cultures (Fig. 5A,B).
Inhibition occurred at tranilast concentrations $100 mM, and at
400 mM no mammospheres were seen. Tranilast reduced cell
survival in these cultures, but even at the highest concentration
(400 mM) almost 50%ofcells survived after 7 d inculture (Fig. S1B).
Note that at concentrations that can be achieved pharmacologically
(100–200 mM) some spheres still formed (although they were
smaller), suggesting survival of sphere-forming cells.
We compared the effects of tranilastwith paclitaxel andetoposide
at variousconcentrations. In Fig. 5A,B, the results obtained withthe
highest concentrations of either paclitaxel (60 mM) or etoposide
(40 mM) tested are shown. Lower concentrations were less effective
(not shown). As seen in Fig. 5A, pharmacological concentrations of
tranilast (100–200 mM) were more effective than these drugs at
reducing the number of mammospheres.
Tranilast is an AHR agonist
As mentioned above, D-CSCs express high levels of AHR.
Since Kerkvliet and colleagues suggested that tranilast is an AHR
agonist [16], we hypothesized that the AHR is a major drug target
in our experiments. To address this, we first confirmed that
tranilast is indeed an AHR agonist. These agonists are strong
inducers of the CYP1A1 enzyme [15], and we found that tranilast
increases CYP1A1 expression in breast cancer cells (Fig. 6A) by
EROD enzymatic assay [26] in vitro. Higher concentrations of
tranilast were required for induction (Fig. 6A) as compared to 3-
methylcholanthrene (3-MC), which is a classic high affinity AHR
agonist [27]. Nevertheless, maximal enzyme induction was higher
in the tranilast cultures, and we speculate this occurred because
tranilast is less toxic than 3-MC. The level of CYP1A1 expression
observed with many agonists reaches a peak and then declines at
higher concentration. This might be related to toxicity or other
mechanisms. CYP1A1 induction was higher in ALDH
hi-sorted
cells derived from the untreated parental cell line (Fig. 6B),
consistent with a higher expression of the AHR by these cells as
determined by flow cytometry (data not shown).
In vivo, tranilast significantly increased CYP1A1 expression in
the liver (Fig. 6C), and induced translocation of the AHR to the
nucleus as analyzed by confocal microscopy (Fig. 6D). This
demonstrates that sufficient drug concentrations are achieved in
vivo by our therapy to activate the AHR. Finally, we performed
binding studies and showed that tranilast competes with 3-MC for
binding to the AHR (Fig. 6E). These in vitro and in vivo findings
are all consistent with AHR agonist activity. The affinity of
tranilast for the AHR (Ki=44 mM; calculated with the Cheng-
Prussof equation) is considerably lower than 3-MC
(Ki=0.035 mM) but, nevertheless, it activates the AHR at
concentrations (50–200 mM) that are achieved in the circulation
of patients treated with tranilast (see Discussion).
The AHR is the target of tranilast in cell proliferation
assays
We analyzed whether blockade of AHR signaling affected
tranilast activity in our assays. The addition of an AHR antagonist
to cultures, a-naphthoflavone (aNF) [15,17], or knockdown of the
AHR with siRNA, completely reversed the activity of tranilast
against cell proliferation of the MDA-MB-231, BT474 and 4T1
cell lines (Fig. 7A–C). The high efficiency of the knockdown was
confirmed by the loss of CYP1A1 induction by EROD assay
(Fig. 7D) and loss of AHR expression by flow cytometric analysis
(Fig. 7E).
Figure 2. Tranilast treatment reduces mammosphere formation and stem cell marker expression. A. Tranilast (200 mM) markedly
reduced the number of primary mammospheres of MDA-MB-231 cell line when compared to the vehicle control (results at d 7) (100X). B. Similar
results were obtained in MDA-MB-231 secondary mammosphere culture. C. Tranilast (200 mM) markedly reduced the numbers and size of secondary
mammospheres (results at d 14) of the BT474 cell line (100X). D. Tranilast caused a significant reduction of mammosphere numbers related to the
number of cells plated as described in Fig. 2A and 2C (mean + SD; ***p,0.0001). Results are the mean of 2 independent experiments in triplicates.
The mean diameter of the mammospheres in tranilast cultures was significantly less than half that of vehicle cultures (not shown). Scale bar: 100 mm.
E,i. Western blots of MDA-MB-231 cell lysates of primary mammospheres show that phosphorylated retinoblastoma protein (denoted here pRB) was
greatly reduced by tranilast. E, ii, iii. Western blots show complete suppression of the stem cell markers Oct 4 and CD133 by tranilast. The data
presented in Fig. 2A–E were all derived from cells grown under mammosphere culture conditions with 200 mM tranilast or vehicle. V = vehicle;
T = tranilast.
doi:10.1371/journal.pone.0013831.g002
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Here, we found that tranilast moderately increases the
expression of the AHR in MDA-MB-231 breast cancer cells
(Fig. 7F,i). Furthermore, we observed in coprecipitation assays that
AHR coprecipitates with CDK4, and this interaction is disrupted
by tranilast (Fig. 7F, ii, iii). It is notable that although tranilast
moderately increased the amount of AHR, the amount of AHR
coprecipitated with CDK4 was decreased in these cells. This
supports the conclusion that tranilast inhibits the binding of AHR
and CDK4. Barhoover et al. [28] reported that in the absence of
an external ligand the AHR interacts with CDK4, and this
promotes the phosphorylation of RB, allowing the cell cycle to
proceed. However, in the presence of an external AHR ligand
(TCDD) the association of AHR with CDK4 was blocked,
Figure 3. Drug-selected cells express higher level of stem cell markers. Phenotyping of mitoxantrone-selected cells. A. Cells from cell lines
MDA-MB-231, BT474, or 4T1 were grown in mitoxantrone-containing medium to generate CSC-like cells (D-CSCs), as described in Materials and
Methods. The cells were stained for ALDH-1 expression by the ALDEFLUOR assay. Silver-filled histograms represent negative control obtained in the
presence of the ALDH-1 inhibitor DEAB, and were used for the gating of the ALDH-1 bright cells (ALDH high). In each histogram, blue lines and
numbers (%) represent the percent of ALDH high cells in mitoxantrone-treated cells, while red lines and numbers (%) represent the percent of ALDH
high cells in the non-treated cells. The figures show that mitoxantrone notably increased the number of ALDH1 high cells. B. MDA-MB-231 cells were
stained for ABCG2, AHR, or c-kit and analyzed by flow cytometry. Mitoxantrone-selected cells (blue lines and numbers [%]) showed a marked
increased in the expression of ABCG2, AHR, and c-kit, as compared to the non-selected cells (red lines and numbers [%]). The gates were positioned
to include the peak of the brightest cells in each histogram. C. Drug selection increased the number of cells expressing the stem cell nuclear marker
Oct-4 (green) in MDA-MB-231 cells, from ,5% without mitoxantrone (non-treated) to ,30% with mitoxantrone (mito), as detected by
immunofluorescent confocal microscopy. The cytoplasm (red) was decorated with Alexa Fluor 568-conjugated phalloidin that binds to actin. The data
in panels A and B are representative of two independent experiments.
doi:10.1371/journal.pone.0013831.g003
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arrest. Our results suggest that tranilast is acting similarly to
TCDD by preventing the association of AHT and CDK4, which
might explain reduced RB phosphorylation (as in Fig. 2D), but
further studies are required to confirm this.
The AHR is the target of tranilast in mammosphere assays
As with proliferation, we found that the anti-mammosphere
activity of tranilast was completely abrogated by siRNA-mediated
knockdown of the AHR (Fig. 8A–E) or addition of aNF to cultures
(8F). Remarkably, mammospheres were completely protected
from the effects of tranilast by these procedures, suggesting that the
AHR is the major and possibly the sole molecular target of this
drug in these assays. Note that the increase in cell death induced
by tranilast in mammosphere cultures was prevented by the AHR
antagonist aNF (Fig. S1B).
Figure 5. Tranilast inhibits mammosphere formation by
mitoxantrone-selected MDA-MB-231 cells. MDA-MB-231 mitoxan-
trone-selected cells were plated for mammosphere formation (1000
cells/well; 96-well plate, Cnt-27 medium) and grown with tranilast (100–
400 mM), or a high concentration of either etoposide (40 mM) or
paclitaxel (60 mM). Control cells were grown with vehicle (2.5% DMSO).
Tranilast decreased the numbers (A) and size (B) of the mammospheres,
such that none were visible at 400 mM. Tranilast appeared more
effective than etoposide or paclitaxel at reducing mammosphere
numbers (mean + SEM; p,0.05 for tranilast at 200 mM versus either
vehicle, etoposide or paclitaxel). The data are representative of two
independent experiments.
doi:10.1371/journal.pone.0013831.g005
Figure 4. Dissociation of mammospheres after treatment with
tranilast. A. MDA-MB-231 and 4T1 cells were selected by growth with
mitoxantrone. The live cells (after a period of growth in mitoxantrone-
free medium) were recovered and then grown in mammosphere
culture. After 7 days mammospheres had formed at high frequency,
and at that point vehicle (V, 1st row; DMSO), paclitaxel (Pax, 2nd row;
20 nM) or tranilast (T, 3rd row; 200 mM) were added to the cultures.
After a further 48 hours in culture mammospheres were reduced in size
but not disrupted in the paclitaxel cultures, whereas they were
completely dissociated in the tranilast cultures. Similar mammosphere
disruption occurred at tranilast concentrations of 100 and 400 mM (not
shown.). B. Tranilast was added to formed mammospheres of different
breast cancer cell lines, as described above for Fig. 4A. Tranilast was
effective at dissociating mammospheres of all breast cancer cell lines
tested. MDA-MB-231, SUM149 and SUM159 (all human), and 4T1
(mouse), are all ER-/PR-/HER-2- (triple-negative) cell lines. BT474 is an
ER+/PR+/HER-2+ (triple-positive) human cell line. The results represent
the mean diameter of mammospheres +/2 SEM, with or without
tranilast. In panels A and B, three experiments yielded similar results.
doi:10.1371/journal.pone.0013831.g004
Inhibition of CSCs
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We have previously shown that tranilast suppresses tumor
growth and metastasis following the injection of 4T1 mammary
carcinoma cells in the mammary fat pad of female BALB/c
(syngeneic to the tumor) mice [12]. Here, to determine whether
tranilast could be effective against human D-CSCs, we injected
mitoxantrone-selected MDA-MB-231 cells i.v. into NOD scid
gamma (NSG) mice to examine lung metastasis, or injected the
cells into the mammary fad pad to examine primary tumor growth
(Fig. 9A–C). These immunodeficient mice lack B and T
lymphocytes (scid phenotype), and also lack NK cells and are
deficient in innate immunity due to knockout of the IL-2Rc chain.
Similarly to our previous results with unselected 4T1 cells [12],
we found that tranilast inhibited the growth of mitoxantrone-
selected D-CSCs injected into the mammary fat pad of female
mice (Fig. 9C). In control mice the tumors grew rapidly and they
had to be terminated, usually before developing metastases. We
attempted to treat mice with aNF (with or without tranilast) to
Figure 6. Tranilast is an AHR agonist. A. CYP1A1 induction (EROD assay) by tranilast or 3-MC (a high affinity AHR agonist). Adherent MDA-MB-
231-derived D-CSCs were pre-treated for 1 h with either tranilast or 3-MC and then assayed for CYP1A1 expression by EROD assay. The enzyme
activity was measured as the product-related fluorescence and expressed as arbitrary fluorescence units per min per mg protein. Tranilast induced
CYP1A1 expression at higher concentrations than 3-MC, but generated higher maximum levels of the enzyme. B. ALDH high and ALDH low MDA-MB-
231 cells, previously sorted by FACS, were allowed to adhere and treated as above. Higher levels of induced CYP1A1 expression were observed in the
ALDH high cells. C. C57BL/6 mice were treated with tranilast twice (300 mg/kg; d 0 and d 1) and terminated on day 2 to recover liver tissue. CYP1A1
(EROD assay) was measured in liver microsomal fraction from tranilast- or vehicle-treated mice. Tranilast induced a significant increase in CYP1A1
enzyme activity (p,0.05; n=5/group), indicating that sufficient drug levels were achieved to exert AHR agonist activity in vivo. D. Mice were treated
with tranilast (T) or vehicle (V) as in Fig. 6C. Tranilast-induced nuclear translocation of AHR in vivo as detected by immunofluorescent confocal
microscopy, further confirming its AHR agonist activity in vivo. Cryo-sections of liver from tranilast- or vehicle-treated C57 mice were stained against
AHR (AF 568, red) and counter-stained with a nuclear-specific stain Sytox Green (green). The arrows indicate the nuclei. The images are representative
of each group (n=5/group). E. Competition of tranilast or unlabeled 3-MC with [3-H]-3-MC for binding to plate-immobilized AHR from mouse liver
cytosol. The data was acquired in duplicate and is expressed as a % displacement of radioactive ligand. Ki=44 mM for tranilast versus 0.035 mM for
the non-labeled 3-MC.
doi:10.1371/journal.pone.0013831.g006
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survival these experiments could not completed.
To test the effect of tranilast on metastatic spread, we used an
i.v. lung metastasis assay, which tests the final steps of metastasis.
MDA-MB-231 cells are not efficient at forming lung metastases
following i.v. injections, but this is improved by injecting CSC-
enriched subpopulations. Thus, Croker et al. [7] reported that
5610
5 ALDH
loCD44
low/2CD24
+ (non-CSC population) MDA-
MB-231 cells injected i.v. into NOD scid gamma mice could
establish themselves in the lungs, but they appeared unable to
grow. However, when they injected the same number of
ALDH
hiCD44
+CD24
2 (CSC-enriched) cells, they observed sus-
tained growth of metastatic cells. In our case, mitoxantrone-
treated MDA-MB-231 cells were markedly enriched for cells with
stem cells markers (e.g., ALDH, Oct-4, c-kit), and we found that
that i.v. injection of 1.5610
5 of these cells into NOD scid gamma
mice generated lung metastases in the majority of the mice. These
were identified histologically at 4 weeks post cell injection
(Fig. 9A,B). In this experiment, we treated the mice with tranilast
(300 mg/kg/d) or vehicle from day -1 to day 21, and terminated
the mice at day 28. In sharp contrast to the vehicle-treated mice
that had metastases, the tranilast-treated mice did not have a single
Figure 7. Tranilast’s anti-proliferative effect is mediated through AHR stimulation. A. The suppressive activity of tranilast on proliferation
of MDA-MB-231 cells was reversed by an AHR antagonist, a-naphthoflavone (aNF). Blockade of tranilast was complete at 1 mM of aNF. B. Blocking
effect of aNF on BT474 cell line at a concentration of 1 mM. C. siRNA knockdown of AHR in MDA-MB-231 cells abrogated the antiproliferative effect of
tranilast. D. The induction of CYP1A1 expression by tranilast in MDA-MB-231 cells was prevented by AHR knockdown. E. Transfection with AHR-
targeted siRNA completely prevented AHR expression by MDA-MB-231 cells as detected by flow cytometric analysis, demonstrating the efficacy of
the knockdown procedure. F. Tranilast blocked AHR binding to CDK4. Western blot analysis of lysates of MDA-MB-231 cells grown in conventional
DMEM-based medium with vehicle (V) or tranilast (T) (200 mM; 48 h culture) was preformed as described under Materials and Methods. Tranilast
enhanced AHR expression, but not CDK4 expression (C i). Immunoprecipitation of lysates of cells grown in vehicle (V) revealed that anti-CDK4
antibody also pulled down AHR, indicating that the two molecules bind to each other, and this binding was significantly disrupted by tranilast (C ii, iii,
**p,0.001). These results are representative of 3 experiments.
doi:10.1371/journal.pone.0013831.g007
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Thus, tranilast completely prevented metastasis of a triple-negative
cell line in this xenotransplantation study.
Discussion
In this study, we show that tranilast has marked inhibitory
activity against CSCs, and this is dependent on the AHR.
Importantly, tranilast was active against previously untreated
CSCs and those that had survived culture with a chemothera-
peutic drug (D-CSCs). We used drug selection of CSCs because
this likely duplicates, at least in part, some events that occur during
chemotherapy of cancer patients. As recently reviewed [4], there
have been two main approaches to isolate CSCs, i.e., candidate
versus operational approaches. In the candidate approach specific
markers are used to sort the cells. These approaches enrich for
CSCs, but do not appear to define the entire CSC population [4].
For instance, in breast cancer, the ALDH
hi marker appears to
identify more CSCs than the classical CD44
+CD24
2/lo markers
[6]. These subpopulations can be further fractionated with other
markers, and there might be several subtypes of CSCs.
In operational approaches, the CSCs are isolated by taking
advantage of CSC features such as sphere formation, or resistance
to radiotherapy and/or chemotherapy [4,8–10,29–34]. Chemo-
therapeutic drugs have been shown to enrich for CSCs both in vitro
and in vivo. Drug-based operational approaches have been
Figure 8. Tranilast’s anti-mammosphere effect is mediated through AHR stimulation. A–D. Mammospheres formed by MDA-MB-231-
derived D-CSCs, transfected with AHR-targeted (A, C) or scrambled siRNA (B, D) were treated with 200 mM tranilast (C, D) or with vehicle (A, B) for
48 h. T= tranilast; V= vehicle. Tranilast dissociated the mammospheres formed from cells expressing AHR (scrambled siRNA), but had no effect on
cells with AHR knockdown (AHR siRNA), demonstrating the AHR is required for this tranilast effect. E. The diameter of mammospheres as a function of
the concentration of tranilast in AHR-expressing versus knockdown cells. F. Tranilast’s anti-mammosphere effect was completely blocked the AHR
antagonist aNF, further confirming the requirement of the AHR. The data is representative of two independent experiments.
doi:10.1371/journal.pone.0013831.g008
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glioblastoma,breast, and colon) [8–10,32–34], and do not represent
a novel approach. Several chemotherapeutic drugs were effective in
these studies, including doxorubicin, etoposide and mitoxantrone,
and the effect does not appear drug specific. ABCG2
+ side
population (SP) breast cancer cells are strongly resistant to
chemotherapeutic drugs, and these CSC-like cells are highly
tumorigenic [33,34]. Drug-induced enrichment of CSCs is clinically
relevant, as shown in treated breast cancer patients [31]. To select
CSC-like cells, we used an in vitro operational approach (drug
selection) based on the existing literature. In view of this, we did not
attempt to duplicate all assays reported in previous publications.
We observed that a 5-day incubation in mitoxantrone resulted
in massive cell death, but 30–50% of the drug-surviving cells
expressed stem cells markers such as ALDH
hi, c-kit, Oct-4 and
ABCG2. The parental cells expressed AHR, but this was also
markedly increased by mitoxantrone selection. Our results are in
accord with previous enrichment for MCF-7 SP cells with
mitoxantrone [29], as well as the ability of ABCG2 to pump
mitoxantrone out of the cells [21,22]. Other investigators have
shown that ABCG2 and c-kit are markers of drug-resistant, highly
tumorigenic SP cells (CSCs) of MDA-MB-231 and MCF-7 cell
lines [33]. Similarly, ALDH
hi is a marker for tumorigenic breast
CSCs [6,7]. Although we found that drug selection enriched for
CSC-like cells, our marker studies suggest the resulting population
is a mixture of CSCs and other cells. This is likely a limitation of all
current breast CSC selection methods.
The mitoxantrone-selected cells were considerably more
efficient at forming mammospheres. Mammospheres formation
depends on CSCs, and growth of breast cancer cells in this assay
results in an enrichment of Oct-4+ CSCs [35]. Furthermore, our
data show that drug-surviving MDA-MB-231 cells (,50%
ALDH
hi cells) injected i.v. into immunodeficient NSG mice form
lung metastases (see below), which is consistent with the presence
of tumor-initiating CSCs. As reported by Croker et al. [7],
CD44
2/loALDH
lo (Aldefluor assay) MDA-MB-231 cells injected
i.v. into NSG mice did not grow after implanting in the lungs.
However, injection of CD44
+ALDH
hi cells generated metastases.
Other authors have also reported that ALDH
hi cells of various
breast cancer cell lines (HCC1954, MDA-MB-453 and SUM159)
have increased metastatic potential, as compared to ALDH
lo cells
[6]. Therefore, we conclude that the mitoxantrone-selected cells
we generated contain a substantial proportion of CSC-like cells.
We previously found that tranilast inhibits the proliferation of
several mammary tumor cell lines including mouse 4T1, rat LA7
(a CSC-like line [36]), and human breast cancer (MDA-MB-231,
MCF-7, SKBR3 and BT474) (Ref. 12 and unpublished data). Of
the human cell lines, SKBR3 and BT474 (HER-2
+ lines) and
Figure 9. Tranilast prevents breast cancer metastasis in a
xenotransplantation model. A. NOD scid gamma mice received a
single i.v. injection of MDA-MB-231-derived D-CSCs (150,000 cells; day
0), and were treated with either vehicle (V) or tranilast (T; 300 mg/kg/d)
from day -1 to day 21. The mice were terminated on day 28 and the
lungs were examined. Lung metastases were observed in the majority
of vehicle-treated mice, but there was not a single metastasis in the
tranilast-treated group. n=10 mice/group. p=0.0015 by Fisher’s exact
test comparing the number of mice with metastases in each group. B.
Metastases in the lungs of a vehicle-treated mouse (H & E staining of
histological slide). The arrows indicate metastatic tumor foci. C.
Inhibition of the growth of primary tumors in the mammary fat pad.
20,000 D-CSC cells were injected in a mammary fat pad at day 0. Mice
were treated with 300 mg/kg/d tranilast or vehicle, starting at d 0.
Tumors were examined as described [12] and volume = length X
(width X width)/2, +/2 SEM (n=7; p,0.05 for tranilast versus vehicle).
doi:10.1371/journal.pone.0013831.g009
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+ line) were moderately more sensitive to tranilast than
MDA-MB-231, but all were suppressed. In the highly metastatic
4T1 cell line, tranilast inhibited TGF-b signaling, ERK1/2 and
JNK phosphorylation, and EMT [12,13]. It also caused reduced
RB phosphorylation and cell-cycle arrest [13]. In vivo [12], it
markedly reduced (.50%) the growth of the primary tumor.
However, its effects on metastasis were more striking, with .90%
reduction of metastases to the lungs and complete prevention of
metastasis to the liver.
Here, we show tranilast strongly inhibits both colony and
mammosphere formation by breast cancer cell lines. Inhibition
occurred at tranilast concentrations $100 mM, and at 400 mMn o
mammospheres were seen. Suppression of mammosphere forma-
tion occurred equally in mammospheres produced by CSCs from
non-treated cells or mitoxantrone-selected cells. Mammosphere
numbers and size were reduced. Tranilast reduced cell survival in
these cultures by up to ,50%. However, at concentrations that
can be achieved pharmacologically (100–200 mM) some spheres
still formed, although they were much smaller, suggesting at least
partial survival of sphere-forming cells.
The phosphorylation of RB and the expression of the stem cell
markers CD133 and Oct-4 were also reduced. Remarkably, when
tranilast was added to mammospheres that were already formed,
at concentrations $100 mM, they were completely dissociated
within 48 hours. This was not due to cell death alone, because at
least 50% of the cells were still alive following dissociation. This is
consistent with our previous observations that tranilast is not
cytotoxic in short-term (2–3 day) cultures of parental (unselected)
cancer cells [12], although in vivo it increased apoptosis in the
tumors of tranilast-treated mice [13]. The dissociation of the
tumor spheres is an important finding, because it suggests that the
anti-mammosphere effect is not solely due to an inhibition of
proliferation. When compared to high levels of paclitaxel or
etoposide, tranilast appeared more effective at reducing mammo-
sphere numbers. Tranilast is an AHR agonist (as outlined below),
and this sensitivity of CSCs to tranilast might reflect high AHR
expression, since mitoxantrone-treated cells expressed higher levels
of this marker. Similarly, ALDH
hi-sorted cells (enriched for CSCs)
expressed higher AHR levels than ALDH
lo cells, and showed
higher levels of CYP1A1 induction when incubated with tranilast.
The effects of tranilast against mitoxantrone-selected D-CSCs
(MDA-MB-231 cell line) were similarly apparent in vivo. Primary
tumor growth in the mammary fat pad was inhibited by .50%.
This is similar to our findings with 4T1 cells injected into BALB/c
mice [12]. We injected these cells i.v. into severely immunodeficient
NOD scid gamma mice (lacking B cells, T cells and NK cells). The
vehicle-treated mice developed metastatic foci in the lungs but, in
sharp contrast, the tranilast-treated mice were free of metastatic
tumor. Thus, it was effective against an aggressive triple-negative,
drug-selectedbreast cancercell line.Theseresultsareinaccordwith
our previous findings of an anti-metastatic effect of tranilast against
4T1 cells in BALB/c mice with normal immunity [12].
We demonstrate that tranilast is an AHR agonist. The AHR is a
receptor for toxins such as TCDD (frequently called ‘‘dioxin’’),
polycyclic aromatic hydrocarbons (PAHs) and many other ligands
[15,16,27]. It is a member of the basic-loop-helix-PER-ARNT-
SIM (PAS) family of proteins and functions as a ligand-activated
transcription factor [15,27]. It is normally latent (bound to Hsp90/
XAP2 chaperon complex) in the cytoplasm. AHR agonists release
AHR from this latent complex, and in the canonical pathway it
then migrates into the nucleus and binds to another transcription
factor denoted aromatic hydrocarbon nuclear translocator
(ARNT). The AHR/ARNT complex binds to dioxin-response
elements (DREs), in the promoters and/or enhancers of hundreds
of genes, and either enhances or suppresses their expression.
Prototypically, there is greatly increased expression of cytochrome
P450 mono-oxygenases genes (CYP1A1, 1B1 and 1A2). The
toxicity of TCDD is dependent on AHR expression, but the
reason for its high toxicity is not well understood, and many AHR
ligands are not notably toxic.
Supporting the activity of tranilast as an AHR agonist we find
that: 1) It strongly induces CYP1A1 expression (a classic marker of
AHR activity) in breast cancer cells. In vivo, in the liver, tranilast
administration induced translocation of the AHR into the nucleus
and increased expression of CYP1A1. 2) Addition of an AHR
antagonist, aNF, to cultures completely reversed the activity of
tranilast against cell proliferation and mammosphere formation.
Tranilast no longer dissociated formed primary or secondary
mammospheres, and protection was complete. 3) Knockdown of
the AHR with siRNA in MDA-MB-231 abolished the activity of
tranilast in the same assays as aNF. The finding that AHR
knockdown prevented the anti-mammosphere activity of tranilast,
such that mammospheres formed normally, strongly supports the
conclusion the AHR is the primary drug target for inhibition in
this assay. 4) Tranilast competed with 3-MC for binding to the
AHR in receptor binding assays. Although tranilast has a much
lower affinity for the AHR than 3-MC, it can induce comparable
expression of CYP1A1 in breast cancer cells when added to
cultures at pharmacological concentrations ($100 mM).
The role of the AHR in toxicology has been studied for decades,
but it is now clear that it has multiple other physiological functions.
Indeed, gene activation through DREs does not readily explain all
the effects of tranilast. However, the AHR can bind to other
transcription factors, and in non-canonical pathways [28] exerts
activities which are compatible with the effects of tranilast and
relevant to breast cancer therapy. As reported by Barhoover et al.
[28], the AHR (without an exogenous ligand) contributes to cell
cycle progression by binding to CDK4 and promoting phosphor-
ylation of RB, but this interaction is disrupted by a ligand (TCDD)
resulting in cell cycle arrest [28]. Thus, in this model, the AHR
without ligand facilitates cell cycle progression, whereas with an
external ligand it is inhibitory. Our data confirms that tranilast also
prevents the association of the AHR with CDK4, suggesting this is a
mechanism for cell cycle arrest. In accord with this, tranilast greatly
reduced RB phosphorylation in mammosphere assays (this study),
and in breast cancer cells grown under conventional conditions
[13]. We speculate that a block of AHR/CDK4 binding explains
the effects of tranilast in reducing RB phosphorylation and blocking
the cell cycle, based on the literature [28], but further studies are
required to establish this. Other mechanisms might also contribute,
because the AHR can also bind directly to the RB protein in a
ligand-dependent way [37].
Interestingly,the AHRantagonizesTGF-b activity,andrepresses
latent TGF-b binding protein-1 (LTBP-1) [38]. LTBP-1 is required
for TGF-b secretion and anchors the latent cytokine to extracellular
matrix components. In accord with this, AHR ligands suppress
TGF-b secretion [38] and the cells of AHR-null mice produce more
TGF-b [39]. In view of this, we speculate that the inhibitory effects
of tranilast on TGF-b production or action are related to AHR
agonism, but this question requires further study. TGF-b appears to
play a role in CSC survival or differentiation [40], and this may be
relevant to our findings. Furthermore, the AHR also exerts ligand-
dependent inhibitory effects on NF-kB signaling [41], which might
also contribute to CSC inhibition [42].
There have been few studies of AHR function in stem cells,
whether normal or CSCs, and its role is unclear. AHR agonists,
such as tranilast, might suppress CSCs by inducing cell-cycle
arrest, or inhibiting production of growth factors and cytokines.
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regulates the proliferation and senescence of these cells [43]. This
appears to be a normal physiological function, but in the presence
of TCDD there is impaired self-renewal and depletion of HSCs.
This might result from unphysiological prolonged stimulation, as
TCDD has a very high affinity for the receptor and is not
degraded, persisting in tissues for years. TCDD is also profoundly
immunosuppressive, through actions on the thymus, peripheral
lymphocytes, dendritic cells and other immune cells (16).
Interestingly, the AHR appears to be an important regulator of
prostatic stem cells [44], and it protects against prostate
carcinogenesis in TRAMP mice [45]. TCDD also impairs
mammary tissue differentiation in mice and protects against
DMBA-induced mammary tumors [46]. In some studies, contrary
to expectations, exposure to TCDD and various polychlorinated
hydrocarbons was associated with a reduced incidence of prostate
and breast cancer [47], possibly through anti-hormonal effects
although mechanisms have not been elucidated. In this respect, it
is important to note that TCDD can induce degradation of the
ERa through E3 ubiquitin ligase activity and exert anti-estrogenic
effects [15]. This suggests that AHR agonists (including some
environmental contaminants) have anti-cancer effects against some
types of tumors but, as a note of caution, they have also been
shown to exert carcinogenic effects. It appears that TCDD can
either enhance or suppress the incidence of cancer depending on
the target cell and other factors [47]. The literature on AHR
agonists reveals that they do not all have the same biological
actions or toxicity, for reasons that are not well understood, and
some appear to be non-toxic endogenous ligands [15,27]. Because
of the promiscuous nature of the AHR, many agonists also target
other molecules, which complicates the interpretation of studies. It
is also unlikely that all agonists can duplicate the many activities of
TCDD. Indeed, weaker agonists such as tranilast may have effects
that are considerably different from those of TCDD, 3-MC and
other strong agonists. Evidently, further studies are required to
delineate the role of the AHR in cancer, and whether different
agonists will have similar effects or not.
The biology of the AHR is complex, and activation of the AHR
results in altered expression of hundreds of genes. In view of this,
there are many ways in which the AHR could inhibit CSCs. The
abilityoftranilastandotherAHRagoniststo blockproliferation may
be important, but it does not completely explain the anti-mammo-
sphere effect we observed. In addition to this, the AHR might act by
suppressing the production of growth factors or adhesion molecules,
or act by other mechanisms, and a considerable amount of future
work will be required to elucidate these mechanisms.
Tranilast is of particular interest as an anti-cancer drug because
of the long clinical experience in using it to treat allergy and
fibrotic disease in Japan and other countries [14]. The toxicity of
tranilast is remarkably low (LD50 of .1 gm/kg in rats) [48]. In
human clinical studies, it is usually administered at a dose of
300 mg/day (divided in 2 or 3 doses), but in some clinical trials it
has been given at doses of 600 to 900 mg/d [49]. At the higher
doses , 11% of patients had liver test abnormalities, which were
reversible, and other side effects were relatively minor. With
continuous administration of 600 mg/d, plasma concentrations of
50–200 mM have been observed [50]. In mice, absorption and
pharmacokinetics appear to be different, and doses of 200 mg/kg/
d (by gavage) or ,550 mg/kg/d (added to chow) generate plasma
levels in the same range as humans receiving 600 mg/d [48,50].
We administered 300 mg/kg/d in our studies, which is a
therapeutically relevant dose.
Most importantly, the AHR is expressed by ER
+ and ER
2
breast cancer cells, and has been found in pre-clinical studies
[17,18] to be an excellent target for the therapy of breast cancer,
including triple-negative subtypes (all cell lines examined were
AHR+). Indeed, AHR agonists inhibited invasive and metastatic
features, and colony formation, of breast cancer cells of various
phenotypes, irrespective of ER, PR or HER-2 status [17]. Our
study was focused primarily on triple-negative cancer cells,
because of a lack of drug targets for this breast cancer cell type,
as opposed to HER2+ or ER+ cell types. However, our results
with BT474 (HER2+/ER+/PR+) demonstrate that tranilast’s
activity is not limited to triple-negative cells. Whether all breast
cancer cell types are sensitive to tranilast warrants further
investigation, but studies with other AHR agonists such as TCDD
[17,18] suggest this will be the case. However, many AHR agonists
are too toxic for clinical use, or have not been tested in humans,
and there is a need to develop non-toxic clinically applicable
alternatives such as tranilast. This is of major interest because the
treatment of triple-negative tumors is problematic due a paucity of
targets. Tranilast is a multi-action, non-toxic AHR agonist drug
that appears effective against CSCs. It inhibits colony formation,
mammosphere formation and metastasis following xenotransplan-
tation, and may find applications in the treatment of breast cancer.
Materials and Methods
Mice
Immunodeficient NOD scid gamma (NSG) mice, and other
mice, were obtained from Jackson Laboratory (Bar Harbor,
Maine). The mice were kept in filtered cages under pathogen-free
conditions. All experiments requiring animals were performed
with protocols approved by St. Michael’s Hospital Animal Care
Committee, under approval identification number ACC940.
Drug
Tranilast (N-[3,4-dimethoxycinnamoyl]anthranilic acid; MW=
327.3)was a kind gift of Dr.Richard Gilbert (St. Michael’s Hospital,
Toronto). It was dissolved in DMSO (in vitro use) or basic buffer (in
vivo use), and applied as described [12].
Flow cytometric analysis and cell sorting
Unless stated otherwise, flow cytometry analysis was performed
by methods we have previously described [12,51]. Staining and
cell sorting for ALDH
hi cells was performed as described by
Croker et al. [7], using the ALDEFLUOR
TM assay kit (Stem cell
technologies, Vancouver, BC). This involves an ALDH-1-
dependent enzymatic reaction generating an intracellular fluores-
cent compound, BODIPY-aminoacetate. Its spectrum is similar to
FITC. The gate to identify bright positive cells (ALDH
hi) is set by
adding an ALDH-1 inhibitor (diethylaminobenzaldehyde, DEAB)
to the substrate mixture to produce a negative control. Aldefluor
staining was performed as recommended by the manufacturer.
The duration of the incubation with the substrate was optimized
for each cell line (15–45 min at 37uC). Surface staining was
performed after ALDH1 reaction, while keeping the cells in the
staining buffer on ice to prevent pumping BODIPY-aminoacetate
out by ABC transporters.
For cell phenotyping, we used anti-human-CD44-AF 647, anti-
human CD24-PE, and anti-human c-kit (BioLegend, San-Diego,
CA), biotinylated anti-human ABCG2 (eBioscience), anti-human/
mouse AHR (Abcam, Cambridge, MA) and corresponding isotype
controls and secondary antibodies.
Isolation of drug-surviving CSCs
D-CSCs were generated in culture as described previously [8–9]
with some modifications. The tumor cells were grown in medium
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(5 nM unless stated otherwise). This resulted in massive cell death;
however, CSC-like cells survived and could be maintained in
culture. After 5 days in drug-containing medium, the cells were
grown in drug-free medium for another 3–5 days before further
studies were performed. These cells formed mammospheres in
culture at high frequency.
Mammosphere culture
Mammospheres were grown in serum-free, low adherence
cultures, with a CnT-27 medium and growth additives (CellnTEC
Advanced cell systems, Bern, Switzerland), as described by Dontu
et al. [52]. Self-renewal capacity of the CSCs was determined by
producing further generations of mammospheres. At each step, the
spheres were dissociated to single cells, and replated under the
previous low-adherence conditions. Briefly, mammospheres were
collected and centrifuged. After careful aspiration of the
supernatant, 0.1% Trypsin/EDTA was added to the respective
cell pellets, incubated for 1 min at 37uC. The resuspended cell
pellet was then passed through a 70 mm sieve, counted and
replated in mammosphere culture. In all mammosphere assays the
size and numbers of mammospheres were quantitated using Image
J software (NIH, USA).
Properties of breast cancer cell lines
Studies by Neve et al. [20] and Kao et al. [53] show that breast
cancer cell lines can be subdivided into similar subtypes as clinical
tumors. Each cell line has a small subpopulation of ALDH-1+ cells
as determined in the Aldefluor assay as previously reported [6].
The cells used in this study were obtained from ATCC, except
SUM 149 and SUM159 (Asterand Inc., Detroit). ER-/PR-/
HER2- (triple-negative) cell lines were MDA-MB-231 (human),
SUM149 (human), SUM159 (human) and 4T1 (mouse). HER2+
cell line: BT474 (human; ER+/PR+). The cells lines were grown
in DMEM, containing 10% FBS, except the SUM149 and
SUM159 lines which were grown according to the supplier’s
instructions (Asterand Inc.).
AHR activation assays
Functionally, expression of the AHR was detected by
stimulating the cells with an agonist and detecting CYP1A1
induction with the 7-ethoxyresorufin-O-deethylase (EROD) assay.
EROD assay in mouse liver microsomal fraction from tranilast-
treated and control mice was performed as described by
McNamee et al [26]. Final concentrations in the assay system
were: 0.05 mg/ml protein, 5 mM 7-ethoxyresorufin, 2 mM
NADPH, and 3 mM MgSO4 in PBS, pH 7.4. The reaction was
performed at 37uC, started by adding NADPH and stopped after
10 min by adding a double volume of the ice-cold methanol
followed by centrifugation to remove the protein pellet. The
concentration of the product, resorufin, was measured at the
excitation wavelength of 530 nm and emission wavelength
590 nm using Carry Eclipse spectrofluorometer.
In the case of cultured cells (MDA-MB-231), 10000 tumour cells
per well in a 24-well plate were pre-treated or not with 10 mM3 -
MC or various concentrations of tranilast in DMSO for 1–2 h at
37uC and rinsed with PBS. Control cells were pre-treated with the
vehicle. The mix containing 5 mM 7-ethoxyresorufin and 3 mM
MgSO4 was added to the pre-treated cells for 10–30 min at 37uC.
After the incubation, the reaction mixture was aspirated and used
for the measurement of resorufin accumulation as above. The cells
were rinsed and used for a protein assay. Enzyme activity was
expressed as an increase in fluorescence intensity (units)/min?mg
protein. Assay was performed in duplicates, using normal, drug-
resistant, ALDEFLUOR-sorted, and AHR-knock-down MDA-
MB-231 cells.
To observe the effect of tranilast on nuclear translocation of
AHR in vivo, the mice were treated with tranilast or vehicle and
terminated 24 h after the last injection. Portions of fresh liver were
fixed in 4% paraformaldehyde, soaked in 15 to 30% sucrose
gradient for cryoprotection, and quickly frozen in O.C.T. solution
on dry ice. 10 m cryo-sections were stained with anti-AHR
antibody and anti-mouse IgG-AF 568 after permeabilization and
blocking and counter-stained with a nuclear dye Sytox green. The
samples were studied by confocal microscopy.
Binding of tranilast to the AHR
Binding of tranilast to the AHR was demonstrated in a
competition assay using cytosolic protein from mouse liver and
[3-H]-3-MC (0.2 Ci/mmol) (Moravek Biochemicals and Radio-
chemicals, Brea, CA). The radioligand was added at the final
concentration 50 nM. The assay was performed essentially as
described by Savouret et al [54]. The protein concentration was
0.85 mg/ml in HEDG buffer containing 1 mM CaCl2. Non-
displaceable binding was assessed by adding dextran-coated
charcoal (Sigma) admixed with 1% ovalbumin in HEDG buffer
to the final concentration 0.15%.
In a modified assay, to minimize the contribution of cytosolic
proteins other than AHR to the retention of the ligands, AHR
from the cytosolic fraction was immobilized on the ELISA plate
pre-coated with monoclonal anti-AHR antibody (1 mg/ml) and
blocked with 2% ovalbumin. The radioactive and non-radioactive
ligands (tranilast and 3-MC) pre-mixed at various ratios in HEDG
buffer containing 1 mM CaCl2 were incubated in this plate for
2.5 h at room temperature. Unbound ligands were washed out
with 0.05% TWEEN in PBS. The dried wells were separated and
placed in the scintillation cocktail for counting. The assay was
performed in duplicates. Both affinity-purified (antibody bound)
and total cytosolic proteins had the same binding capacity for
tranilast, expressed as percent displacement of the radioligand.
IC50 values were converted into the apparent Ki value using the
Cheng-Prussoff equation [55], where Ki=IC 50/[1+(L/KD)]. In
this formula, Ki is the inhibition constant for a drug (the
competing ligand, i.e. tranilast or another non-labeled ligand): it
represents the concentration of the competing ligand in a
competition assay which would occupy 50% of the receptors if
no radioligand were present. L is the concentration of free
radioligand used in the assay, and KD is the dissociation constant
of the radioligand for the receptor. The Ki value for a competing
ligand is an estimate of its binding determined in an independent
binding or functional assay under similar conditions.
AHR siRNA knockdown
AHR expression was determined by flow cytometric analysis
and western blotting using anti-AHR antibodies from Abcam.
AHR expression was knocked down with AHR-targeted SureSi-
lencing siRNA (SA Biosciences/Qiagen). Under optimal transfec-
tion conditions using an equimolar mixture of three RNA species
(A, B, and C) and SureFect transfection reagent (SA Biosciences/
Qiagen), AHR expression was suppressed as determined by loss of
CYP1A1 induction (Fig. 7D) and loss of AHR expression by flow
cytometric analysis (Fig. 7E).
Colony forming assay
These assays were carried out according to Korah et al, 2000
[56]. Briefly, 20,000 cells in 0.5% agar (Bacto-Agar, Difco
Laboratories) were layered on preformed 0.8% agar layer using
a 35 mm Petri dishes (Non tissue culture, Fisher Scientific). The
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vehicle (0.8% DMSO) respectively. After plating, DMEM
containing 10% FBS was added to each plate. Colonies was
counted under the microscope using a low magnification (4x) and
photographed after 12 days.
Western blotting
Cell lysates were prepared and Western blotting performed as
described [57]. Briefly, the cells were lysed in lysis buffer (50 mM
Tris pH 7.6, 150 mM NaCl, 0.1% NP-40) containing a cocktail of
protease inhibitors (PMSF, leupeptin, pepstatin and aprotinin). 5X
concentrated Laemmli sodium dodecyl sulfate (SDS) sample buffer
containing b-mercaptoethanol was added to the cell lysates and
incubated for 5 min in a boiling water bath, vortexed and an
appropriate amount loaded onto a 12% SDS-PAGE for Western
blot analysis.
The following antibodies were used: Rabbit anti-pRB, mouse
anti-CDK4, rabbit anti-CDK4 (Santa Cruz Biotechnology, Santa
Cruz, CA,), mouse anti-human b-actin (Sigma-Aldrich, St. Louis,
MO,) rabbit anti-Oct-4 (Cell Signaling, Beverly, MA), rabbit anti-
CD133, mouse anti-AHR (Abcam, Cambridge, MA).
Breast cancer xenotransplantation experiments
6 weeks old female NOD scid gamma (NSG) mice (Jackson
Laboratories) received a single intravenous injection (tail vein) of
tumour cells, and were treated with either 300 mg/kg/d tranilast or
vehicle (1% NaHCO3) by gavage, as we described before [12]. The
physical condition of the mice was monitored daily. Metastatic
disease was evaluated in lung H&E stained histological sections.
Statistical Analysis
Statistical analyses were performed with the GraphPad Prism
3.0 program (GraphPad Software Inc., San Diego, CA). In each in
vitro experiment, the significance of differences between experi-
mental and control results was determined by either Student’s t
test or analysis of variance (ANOVA). Results are expressed as the
mean 6 SEM, unless stated otherwise. For the lung metastasis
study, the difference in the number of mice developing metastases
between groups was analyzed by Fisher’s exact test. In all
experiments p,0.05 was considered significant.
Supporting Information
Figure S1 Replating of cells cultured with tranilast, and
decreased cell survival. A. MDA-MB-231 cells were grown with
200 uM tranilast for 7 days, as described in the legend of Fig. 2A.
Live cells were replated in mammosphere culture without tranilast.
The figure shows that these surviving cells could still form
mammospheres. B. Mitoxantrone-selected MDA-MB-231 cells
were grown in mammosphere cultures with tranilast for 7 days as
described in the legend of Fig. 5. The cells were recovered and
examined for survival by trypan blue dye exclusion. Tranilast
decreased survival in a dose dependent way, but even at the
highest concentration a substantial proportion of cells survived.
The AHR antagonist aNF prevented cell death.
Found at: doi:10.1371/journal.pone.0013831.s001 (9.82 MB TIF)
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